Introduction
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and has a poor prognosis and low survival rate (1) . A large proportion of HCC cases occur in less-developed countries in Asia and Africa, and are typically associated with chronic hepatitis virus infection (mainly HBV and HCV). Interestingly, while the incidence of HCC in less-developed areas is decreasing because of vaccination, the incidence of HCC in well-developed countries, including the United States and Europe, has increased in the last 20 years (2, 3) . The etiology of this increase in HCC in developed countries remains to be elucidative, but it is likely to involve HCV and metabolic factors such as obesity and diabetes (4, 5) . However, there are currently limited therapeutic regimens available for the effective treatment of HCC. The fact that HCC exhibits a high recurrent rate after resection and is resistant to conventional chemotherapy and radiotherapy renders the disease a very serious health problem at the current time.
In addition, hepatic steatosis (fatty liver), which manifested as an excess accumulation of lipids in hepatocytes, is associated with hepatitis virus infection, various drugs, nutritional factors, and multiple genetic defects in energy metabolism. Fatty liver is a vulnerability factor that can promote liver damage and inflammation, which results in a further progression to cirrhosis and HCC (6) . In order to treat fatty liver and protect against the development of more severe forms of end-stage liver disease and cancer, the discovery Resveratrol (trans-3,5,4'-trihydroxystilbene; RSV) is a polyphenol found in a wide variety of plant species. RSV has been shown to exert beneficial effects across species and various disease models; it can prevent or slow the progression of a wide variety of illnesses, including cancer, cardiovascular disease, diabetes and metabolic disease, as well as enhance stress resistance (7, 8) . For liver diseases, previous studies have demonstrated the protective effects of RSV against alcohol-induced fatty liver and liver injury in mice (9, 10) .
This protective action of RSV in preventing the development of alcoholic fatty liver seems to be associated with an upregulation of the SIRT1 and AMPK signaling pathways in the livers of the ethanol-fed mice (11) . The beneficial effect of RSV has also been shown in a rodent model of non-alcoholic fatty liver disease where the disease is induced by a protocol involving a high carbohydrate-fat free modified diet and fasting (12) .
The anti-cancer potential of RSV in HCC has been investigated in xenografted nude mice and in rodent models carrying transplanted hepatome cells; in addition, the chemopreventive effect of RSV has also been evaluated in chemical carcinogen-induced HCC in rats (13) . Bishayee and Dhir (2009) (14) applied a two-stage protocol of rat hepatocarcinogenesis involving a single intraperitoneal injection of diethylnitrosamine (DEN, 200 mg/kg) followed by promotion with phenobarbital (PB, 0.05%) in the drinking water. Suppression of oxidative stress and the inflammatory response as well as alternations Therefore, an animal model of hepatocarcinogenesis mimicking the spontaneous progression of HCC development in human patients is required, and this has not yet been explored.
In this study, we investigate the therapeutic effects of RSV on HBV-associated liver damage and fatty liver during the early stages of pathogenesis, and evaluate the potential chemopreventive activity of RSV on HBV-associated HCC at a later pre-cancerous stage.
This was done using a transgenic (TG) mouse model that expresses the HBV X protein (HBx) specifically in the hepatocytes. The HBx TG mice spontaneously develop HCC at between 13 months and 16 months of age. The HCC that develops in these HBx TG mice exhibits a well-differentiated morphology of the trabecular pattern, which is similar to that observed in human HCC (17 physiological conditions (18) . In addition, we also examined the changes in the hepatic gene expression profile and signaling pathways before and after RSV treatment at various time points, and compared these between the HBx TG and wild-type (WT) mice. This allowed us to explore the potential molecular mechanisms through which the protective effects of RSV may work.
Materials and Methods

HBx transgenic (TG) mice
We have previously generated four lines of HBx TG mice, namely A105, A106, A110 and A112, in the C57BL/6 background (17). All of the HBx TG lines develop HCC. In this study, all the animal experiments used male mice of the line A106; this line develops HCC faster than the other three TG lines (17) . All of the mice were housed in a specific pathogen free facility. All of the animal protocols are consistent with the recommendations outlined in the "Guide for the Care and Use of Laboratory Animals" (Washington, DC, National Academy Press). The Institutional Animal Care and Use Committees of the National Yang-Ming University had specifically approved this study (approval number 981207).
Resveratrol (RSV) administration
To study the therapeutic effect of RSV on the fatty liver and early stage of liver and delivered to the mice by oral administration using a feeding needle once a day. Mice were sacrificed at 2, 3, 7 and 14 days after RSV administration. To study the chemopreventive effect of RSV on the pre-cancerous stage of liver carcinogenesis, 12-month old HBx TG male mice and their WT male littermates were used. In this case RSV (Sigma R5010) was mixed with powdered chow at a concentration of 3g/12.5 kg of food to provide a dose of 30 mg/kg/day for a mouse (average body weight 30g, eating 4g of chow daily), and pellets were then reconstituted; this special diet was prepared by Research Diets, Inc. (New Brunswick, NJ 08901, USA). Mice were sacrificed at 16-month old after RSV supplementation to the chow for 4 months. Liver tissues and sera were collected for pathological and biochemical analysis.
Pathological analysis
The number and size of liver nodules were measured at mouse sacrifice. The livers were collected, fixed with formalin and embedded in paraffin. Liver sections were subjected to hematoxylin-eosin (H&E) staining. Fat accumulation was demonstrated by oil red-O staining of cryostat frozen sections (19) . Ultrastructural changes in the liver were examined by transmission electron microscopy (TEM) (20 
Intracellular ROS and GSH levels
Primary hepatocytes were isolated from mouse livers using the two-step collagenase perfusion method (21) . Intracellular ROS levels were determined using an oxidative sensitive fluorescence dye, dichlorodihydrofluorescein diacetate (DCF-DA; Molecular Probes) (18) . Intracellular GSH levels were determined using a cell-permeable nonfluorescent dye monochlorobimane (MCB; Molecular Probes) that becomes highly fluorescent following reaction with intracellular glutathione (18) .
RNA analysis
Total RNA was isolated from mouse tissues using TRIzol Reagent (Life Technology).
Slot blot hybridization was performed as previously described (22) . We execute reverse transcription with 2μg of total RNA using oligo-d(T) as primer and Superscript III reverse transcriptase (Invitrogen Life Technologies). The real-time quantitative PCR was carried out on a Roche LightCycler 480 instrument using a TaqMan probe. All amplifications were carried out in triplicate for each RNA sample and primer set, and all measurements were done using RNA samples from three individual mice. The amount of total input cDNA was normalized using Hprt as an internal control. 
Western blotting and immunohistochemistry (IHC) analysis
Western blotting was performed as described previously (23) 
Statistical analysis
The results are presented as mean ± SD from at least three independent experiments.
Comparisons between two groups were done using a Student's t test. A p value of <0.05 was considered significant.
Results
RSV promoted recovery from fatty liver and the early stages of liver damage
The animal protocol for RSV treatment is shown in Figure 1A ; RSV was used at a concentration of 30 mg/kg/day, which is a feasible daily dose for human (24 pathology including fatty changes (microsteatosis), pleomorphic and bizarre nuclei, ballooning of the hepatocytes and abnormal arrangements of the sinusoid, all of which were clearly detectable in the HBx TG mice (Fig. 1B a) . Interestingly, oral administration of RSV (30 mg/kg/day) from 4 to 6 weeks of age reduced liver damage and regressed the histopathology of the HBx TG mice in a time-dependent manner ( Fig. 1B b-d) . The liver pathology of the HBx TG mice recovered significantly after receiving RSV for 7 days ( Fig. S1 ). However, the value for serum ALT in the HBx TG mice was significantly reduced at day 14 after receiving RSV. Importantly, no obvious difference in the serum ALT values could be detected in the WT mice with or without RSV treatment, indicating that RSV has no toxic effect on the liver (Supplementary Fig. S2) . Thus, our results demonstrated that RSV treatment results in recovery from fatty liver and that RSV exerted therapeutic effects during the early stages of liver pathogenesis in the HBx TG To study the efficacy of RSV on hepatocyte ultrastructure, HBx TG livers after receiving RSV were examined by transmission electron microscopy. In the WT mice, no ultrastructural abnormalities were detected with or without RSV treatment ( Fig. 2A and B) .
In the HBx TG mice without RSV, severe ultrastructural alterations were observed in the hepatocytes, including disorganization of rough ER and degeneration of the nuclear envelope and mitochondria ( Fig. 2C and D) . After receiving RSV, most of the ultrastructural abnormalities were absent at 14 days ( Fig. 2E and F ) and seem to have completely recovered at 30 days ( Fig. 2G and H) . Quantification further supported a recovery in mitochondrial volume density among the HBx TG hepatocytes after receiving RSV when compared with WT hepatocytes (Fig. 2I) (25) . Previously we have showed that there are persistently increased levels of ROS during liver carcinogenesis of HBx TG mice (18) . To study the antioxidant activity of RSV in the liver, the intracellular GSH and ROS levels of the hepatocytes were monitored. Indeed, the intracellular GSH levels were significantly increased (Fig. 2J) , whereas the intracellular ROS levels were significantly reduced after receiving RSV for 7 days (Fig. 2K) . These results clearly showed that RSV exhibits antioxidant activity in the liver and that it can efficiently reduce the intracellular To study whether hepatocyte proliferation and liver regeneration were affected by RSV, the Ki67 cell proliferation marker was examined by immunohistochemistry staining of liver sections. Our results indicated that Ki67-positive cells were obviously increased after RSV administration (Fig. 3A) . In WT mice, proliferation of hepatocyte decreased gradually from 4-week old to 8-week old during maturation (Fig. 3B ): 4-week old (2.64±0.16%) AE 5-week old (1.2±0.17%; H 2 O 7d) AE 6-week old (0.74±0.13%; H 2 O 14d) AE 8-week old (0.21±0.03%; H 2 O 30d). In the WT mice treated with RSV, hepatocyte proliferation was not affected after receiving RSV for 3 days; however there was a lower but significant stimulation after receiving RSV for 7 days. Furthermore, the phenomenon of enhanced proliferation disappeared after receiving RSV for 14 days (Fig. 3B) . In the HBx TG mice, quantification revealed that after receiving RSV for 3, 7, and 14 days, there was a significant increase in the number of Ki67-positive hepatocytes found in treated TG mice compared to the untreated TG mice (Fig. 3B) . Importantly, the proliferation of hepatocytes in the HBx TG mice went back to a basal level after receiving RSV for 30 days; this is the time when the animal has completely recovered from all the liver pathology and 
ultrastructure abnormalities following treatment with RSV (Fig. 3B) . These results suggested that the enhanced hepatocyte proliferation and liver regeneration induced by RSV helps to replace damaged cells in the HBx TG mice and this may contribute in part to the chemotherapeutic effect of RSV on fatty liver.
RSV inhibited lipogenic gene expression in the HBx TG livers
To investigate whether HBx gene expression is affected by RSV and whether this might contribute to the regression of morbid liver pathology after RSV administration, expression of the HBx gene was examined. Our results revealed that the mRNA level of the HBx gene was not inhibited by RSV in the HBx TG mice (Fig. 4A and Supplementary Fig. S3A ).
To dissect the molecular mechanisms underlying the beneficial effects of RSV on HBx-mediated fatty liver and histopathology at the early stage of liver damage (4-to 6-week old), we examined the expression of lipogenic genes and the genes related to lipid metabolism in liver. Previous studies have shown that HBx induces lipid accumulation and fatty liver through transcriptional activation of Srebp1-c (sterol regulatory element binding protein 1, isoform c), and peroxisome proliferator-activated receptor gamma (Pparγ) (26, 27) . Srebp1-c is a key regulator of lipogenic genes in liver (28) . Interestingly, there was an age-dependent decrease of Srebp1-c expression in the liver of WT mice. However, the level of Srebp1-c mRNA was significantly increased in the HBx TG mice at around 3-month old 
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and thereafter, compared with age-and sex-matched WT mice (Fig. 4B) . Although there was no obvious difference in the expression levels of Srebp1-c between WT and HBx TG mice from 4-to 6-week old, our result revealed that specifically in the HBx TG mice, RSV significantly reduced Srebp1-c mRNA expression as early as 2 days after receiving the RSV (Fig. 4C) . Subsequently, expression levels of the downstream target genes of Srebp1-c, namely acetyl-CoA carboxylase (Acc) and fatty acid synthase (Fas), were found to be reduced after the expression of Srebp1-c was lowered ( Fig. 4D and E) . However, expression of the Srebp1-c target gene stearoyl-CoA desaturase 1 (Scd1) was not affected by RSV (Supplementary Fig. S3B ). In addition to Srebp1-c, Pparγ is suggested to be a key regulator for lipid uptake and synthesis in liver (29, 30) . Our results revealed that RSV also decreased the expression of Pparγ after RSV had been given for 3, 7, and 14 days in the HBx TG mice (Fig. 4F) .
Inhibition of LXRĮ seems to be the early event upstream affecting Srebp1-c in the HBx TG liver after receiving RSV
Previously studies have shown that HBx induces expression of liver X receptor (LXR)
and its lipogenic target genes, including Srebp1-c and Ppar, in HBx TG mice (27, 31) . Our results revealed that RSV reduced the expression of LXRĮ mRNA as early as 2 days after receiving RSV (Fig. 4G) ; however, RSV had no effect on the expression of LXRȕ in either WT or HBx TG mice (Supplementary Fig. S3C ). Moreover, we also examined whether RSV affects the activation of Akt by phosphorylation, which has been implicated in the HBx-mediated survival signaling (32) and the activation of Srebp1-c (26). Our results did not show a significant difference in the p-Akt/Akt ratios of HBx TG mice with or without RSV treatment (Supplementary Fig. S4 ).
Furthermore, because Srebp1-c is also modulated by AMP-activated protein kinase (Ampk) during control of lipid metabolism in the liver (33, 34), we monitored the effect of RSV on Ampk activity by examining the protein levels of phosphorylated Ampk (pAmpk) and total Ampk. We detected a significant increase in the pAmpk/Ampk ratio at day 3, but not at day 2, after the mice had received RSV in both the WT and HBx TG mice ( Fig. 4H and I). This activation was one day after the decrease in Srebp1-c in the RSV treated HBx TG mice (Fig. 4C) , which suggests that Ampk signaling is unlikely to be the upstream regulator responsible for the RSV-mediated Srebp1-c inhibition in the HBx TG mice.
Moreover, since RSV is an activator of SirT1 (35); we sought to examine the effect of RSV on the hepatic SirT1 activity and gene expression in the RSV treated HBx TG mice.
Our results revealed that there was a significant increase in SirT1 enzymatic activity (1.5-to 2-fold) after receiving RSV for 7 and 14 days in both the WT and HBx TG mice ( Supplementary Fig. S5A ). We further examined the SirT1 protein level in the various livers, and found a similar magnitude of change in enzymatic activity after receiving RSV Since RSV has a beneficial (therapeutic) effect during the early stages of liver pathogenesis, we further tested the preventive effect of RSV on the later stages of HBx-mediated HCC development. RSV (30 mg/kg/day) was orally administrated to HBx TG and WT mice from 12-to 16-month old (Fig. 6A ). In the pre-cancerous mice at 12 months of age and before receiving RSV, hyperplastic nodules measuring between 0.5 to 2.5 mm in diameter could be detected in about 67% of the HBx TG mice ( Supplementary   Fig. S6A ). Furthermore, there was an 80% incidence of HCC in the 16-month old HBx TG mice without any treatment ( Fig. 6B and Supplementary Fig. S6B ) (17) . In WT mice, our results showed that there was no detectable toxicity after receiving RSV for 4 months and there was also no difference in body weight and serum ALT level (a liver damage marker) between the mice treated with RSV and the control group (Fig. 6C and Supplementary Fig.   S7 ). Notably, in the HBx TG mice, there was a significant delay in liver carcinogenesis and a remarkable decrease in HCC incidence after receiving RSV for 4 months. Specifically, no grossly identifiable nodules could be detected in 15% (3/20) 
pathologically confirmed to be benign tumors ( Fig. 6D and Supplementary Fig. S8 ). Out of all the pre-cancerous HBx TG mice, only 15% (3/20) developed HCC. This is a significant reduction after RSV treatment compared to the incidence of HCC in HBx TG mice that have not been treated with RSV, namely 15% compared to 80%, respectively, which is a 5.3-fold reduction of HCC in the RSV treated HBx TG mice compared to the control mice.
Discussion
The central finding in this work is that RSV has therapeutic effects on the early stages of HBx-mediated liver damage, reversing fatty changes and producing a recovery in liver histopathology. Moreover, this study provides evidence for the first time that RSV at 30 mg/kg/day exerts a significant chemopreventive effect on HBx-mediated HCC. Specifically, RSV exhibits anti-carcinogenesis properties by significantly decreasing cancer incidence and delaying the progression of spontaneous HCC in the HBx TG mice.
The molecular mechanism underlying the chemotherapeutic effects of RSV on HBx-induced fatty liver and liver damage seems to be attributable to the pleiotropic actions of RSV (summarized in Figure 5 ). These actions involve the following. 
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TG mice. The inhibition of lipogenesis may also be attributable to an increase in the activities of Ampk and SirT1, which can be detected 7 days after receiving RSV in the HBx TG mice. Previously, the RSV-mediated increase Ampk and SirT1 activity has been documented to be associated with the alleviation of alcoholic fatty liver in mice (11) .
Secondly, RSV treatment leads to a transient stimulation of liver regeneration that helps to replace damaged hepatocytes in HBx TG mice. Importantly, the proliferation of hepatocytes in the HBx TG mice returned to the basal level of a resting adult liver when the animal had completely recovered from all the pathology and ultrastructure abnormalities; this was after receiving RSV for 30 days. Thirdly, RSV enhances antioxidant activity in the liver by, at least in part, increasing intracellular level of GSH. The increased GSH and decreased lipid content in the hepatocytes of HBx TG mice may both contribute to the reduction in the intracellular ROS after RSV treatment. Previous studies have revealed that RSV has antioxidative properties that can increase hepatic GSH and protect the liver against oxidative stress induced by partial hepatectomy (36) and CCl 4 intoxication (37).
Here, we provided further evidence that RSV also protects the liver from oxidative damage mediated by HBx protein in mice. support the idea that fatty liver is one of the risk factors promoting the development of HCC in association with HBV and HCV (38) . Accordingly, eliminating the risk factor of fatty changes and histopathological damage by treating with RSV at an early stage should help to protect the liver against HBx-mediated carcinogenesis, and retard the progression to advanced liver disease and subsequent HCC at the later stage.
The overall safety of RSV has been documented in several in vivo studies. RSV is well tolerated and non-toxic in rodents from low doses (20 mg/kg/day) to high doses (up to 750 mg/kg/day) in a 28-day or 90-day studies (39) (40) (41) . Only at a very high dose (3000 mg/kg/day) of RSV, which is at least 30 times the routine human dose (the dose as high as 7.5 g per day has been suggested for humans, which is equivalent to a dose of 100 mg/kg/day for a 75 kg person) (7), did rats exhibit clinical signs of toxicity as well as a reduced body weight and food consumption after 4 weeks of receiving RSV. In addition, renal toxicity and nephropathy were also observed in these rats (42) . In the present study, our results revealed that oral administration of RSV at 30 mg/kg/day over a period of 4 months seems to have no obvious negative effect that is detrimental to the whole organism.
In WT mice, the body weight and serum ALT level did not differ between mice treated with RSV and the control group over the whole treatment period. Moreover, histopathological 
